Gianfranco Nazzi – CEO, Almirall
Almirall CEO Gianfranco Nazzi dives into the new strategic focus of the global biopharmaceutical company with HQ in Barcelona as it seeks to serve the European medical dermatology market. The…
Almirall, S.A. is a Spanish pharmaceutical company, with headquarters in Barcelona, founded in 1943.[4]
In 2016, it generated a total revenue of 859.3 million € [5] and became the leading pharmaceutical company in R&D investment in Spain.
With over 1,975 employees (2016), it has a presence, through its 13 affiliates in Europe and the United States.
Almirall collaborates with various public and private entities, such as the Centro Superior de Investigaciones Científicas (CSIC), the Instituto de Investigación Biomédica and the Parc Científic de Barcelona in Spain. Highlighted among the international alliances are those with the Imperial College of London (United Kingdom) and the National Institute of Health (NIH) in the United States. Almirall participated in the creation of the Barcelona Respiratory Network Foundation. In Europe, the company has contributed in several projects with the Innovative Medicines Initiative (IMI).
Almirall CEO Gianfranco Nazzi dives into the new strategic focus of the global biopharmaceutical company with HQ in Barcelona as it seeks to serve the European medical dermatology market. The…
Rui Ferreira Dos Santos, country manager for Spanish pharmaceutical company, Almirall provides readers with an update on the company’s new medicines and how their global strategy to become dermatology specialists…
Bertil Lindmark, Almirall’s chief scientific officer, discusses the state of R&D in Spain today and outlines the key strategies the company is taking to provide valuable medicines and cutting-edge technologies…
Eduardo Sanchiz took over as CEO of Spain’s flagship pharmaceutical company Almirall in 2011, after Jorge Gallardo stepped down in this role while staying as Chairman of the Board. Many…
Israel Garcia, general manager of Spain for Almirall, discusses market access issues in the company’s home country and highlights the affiliate’s commitment to internal R&D. What was the reason for…
Almirall Portugal stopped all commercial activity in 2011 to focus only on the market access of new, innovative products being introduced through the organization’s active R&D pipeline. Country Manager Rui…
Having only arrived on the market last year, the GM of Almirall in Canada explains the company’s regulatory struggles, the utilization of Almirall’s global R&D infrastructure in Canada as well…
Almirall was opened through the acquisition of Hermal in 2007. What impact did that have on Almirall’s operations in central Europe, and where does Austria fit in Almirall’s picture today?…
Please can you give us a brief rundown of the last few years in the Mexican pharmaceutical and how the various regulation changes such as the new drug registration process…
The UK is leading the biotech turn, and is recognized as the largest biotech market in Europe. Why did Almirall only decide to enter this market until late 2007? Almirall…
Jesús Cristóbal, CEO of Texpol, the market leader for single-use surgical dressings in Spain, describes the company’s beginnings and his role in its success. Cristóbal goes on to share his…
Miriam Rodriguez, general manager of Aspen Pharmacare Iberia, highlights the steps she has taken to set up the affiliate and how her past experiences have helped her. Furthermore, she breaks…
Marc Comas, managing director of Accord Healthcare Iberia, highlights the footprint of the company as the leading generics and biosimilars player in the Spanish hospital sector and how his early…
Jesús Sobrino, area head of UCB Iberia, and global leader for UCB’s Patients Experience Program, discusses the significance of the affiliate, which makes up 15 percent of UCB’s European sales,…
With cost pressures mounting, Spain is increasingly turning towards digital solutions to maintain the high levels of care provided by its healthcare system. Spain is at a point of…
On Becton Dickinson’s 40th anniversary in Spain, Lourdes López Jiménez, general manager of BD Spain & Portugal, introduces BD’s strong manufacturing footprint in the country and emphasizes the importance of…
Nabil Daoud, president of Lilly Spain, Portugal and Greece, highlights the importance of Lilly’s Spanish operations to the global group; Spain being the only country outside to hold manufacturing, pre-clinical…
Spanish pharma is performing well-above other industries in terms of the percentage of women it employs in leadership positions. Spanish-native Belén Garijo, global CEO of Merck Healthcare since January 2015,…
Javier Hidalgo, CEO and president of Tedec-Meiji Farma, highlights the main challenges he faces and how he positions the company as the preferred partner of choice. Furthermore, he offers his…
Juan Naya, CEO of Isdin, highlights the international expansion and plan of the Spanish skincare company and how his past experience at NASA has helped him in his current role.…
Luciano Conde, CEO, and Jose Luis Fumanal, VP of Sales and Marketing at Noventure, discuss how they set up the company in 2015 and their secret to achieving success in…
Maria Vila, regional vice-president for Spain and Portugal at Medtronic, highlights how she managed the integration of Covidien in Europe and where Medtronic stands today in Spain. Furthermore, she highlights…
See our Cookie Privacy Policy Here
